MSc Public Health Programme, University of London International Programme / London School of Hygiene and Tropical Medicine, London, United Kingdom.
Department of Public Health, Environments and Society London School of Hygiene and Tropical Medicine, London, United Kingdom.
PLoS One. 2020 Dec 7;15(12):e0243424. doi: 10.1371/journal.pone.0243424. eCollection 2020.
In October 2007, the Japanese Health Authority directed that precautions be added to antidepressants (ADs) labelling regarding suicide risk among young people. This study evaluates the impact of the labelling change on AD prescriptions and Japanese adolescent suicide rates.
We compared AD prescription rates per 100,000 population as a primary outcome. The intervention group comprised adolescents (10-24 years), while the control group comprised adults (25-64 years). We defined the pre-intervention period as January 2005 to October 2007 and post-intervention as November 2007 to February 2013. Monthly prescription rate data from a commercial claims database were triangulated with annual suicide rates in Japan. We performed segmented regression analysis for the prescription rates, using a quasi-Poisson model, and tested for level and trend changes.
The commercial claims database included 152,686 adolescents and 195,251 adults during the pre-intervention period and 846,367 adolescents and 1,352,453 adults during post-intervention. Post-intervention, the overall AD prescription rates decreased only in adult males (-95.8 prescription per 100,000) but increased in all other groups. The mean annual suicide rate increased in adolescent males (+1.5 suicides per 100,000) but decreased in all other groups. Overall, the upward trend became moderate or inverse in all groups post-intervention but with a large difference between males and females. The suicide rates rose slightly in adolescents but began declining in adults a year post-intervention. In females, changes in level, trend, and suicide rates were very small in both adolescents and adults.
Contrary to expectations, the mean prescription rates only decreased in adult males, but not in adolescents, regardless of gender. Downward level and trend change were clearly observed in adult males but not in adolescents, the original target of the updated warning. There were no clear temporal associations between suicide rates and the labelling change in either group.
2007 年 10 月,日本卫生部门指示在抗抑郁药(AD)标签上增加关于年轻人自杀风险的预防措施。本研究评估了标签变更对 AD 处方和日本青少年自杀率的影响。
我们比较了每 10 万人的 AD 处方率作为主要结果。干预组包括青少年(10-24 岁),对照组包括成年人(25-64 岁)。我们将干预前时期定义为 2005 年 1 月至 2007 年 10 月,干预后时期定义为 2007 年 11 月至 2013 年 2 月。使用商业索赔数据库逐月处方率数据,并与日本每年的自杀率进行三角剖分。我们使用拟泊松模型对处方率进行分段回归分析,并测试水平和趋势变化。
商业索赔数据库包括干预前时期的 152686 名青少年和 195251 名成年人,以及干预后时期的 846367 名青少年和 1352453 名成年人。干预后,只有成年男性的 AD 总体处方率下降(每 10 万人减少 95.8 份处方),而其他所有群体的处方率均增加。青少年男性的平均年自杀率增加(每 10 万人增加 1.5 例自杀),但其他所有群体的自杀率均下降。总体而言,干预后所有群体的上升趋势变得缓和或反转,但男女之间存在较大差异。青少年的自杀率略有上升,但成年后的第一年开始下降。女性在青少年和成年人中,无论是在水平、趋势还是自杀率方面的变化都非常小。
与预期相反,无论性别如何,成年男性的平均处方率仅下降,而青少年则没有。在原始目标人群青少年中,下降的水平和趋势变化并不明显,而在更新警告的目标人群成年男性中则很明显。在两组人群中,自杀率与标签变更之间均没有明显的时间关联。